Neziri Dashurie, Pajenda Sahra, Amuge Rebecca, Ilhan Aysegul, Wewalka Marlene, Hörmann Gregor, Zauner Christian, Wagner Ludwig
Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
Ugandan Christian University of Mbale, Mbale, Uganda.
J Nephropathol. 2016 Apr;5(2):65-71. doi: 10.15171/jnp.2016.13. Epub 2016 Mar 31.
Acute kidney injury (AKI) is a life threatening condition. Despite intensive care treatment the occurrence cannot be predicted as very little indicators exist for direct measurement when tubular epithelial cell injury takes place. We therefore searched for novel peptide indicators expressed at intracellular level at the proximal kidney tubule for its appearance in urine samples.
Establishing a test for urinary C20orf116 protein measurement.
Generation of immunoreagents against C20orf116 also named DDRGK1. These were used to measure its presence in urine collected at 8-24 hours interval in a prospective study from 99 ICU patients at 4-6 time points. These patients received therapy because of serious infection and were categorized into 4 groups.
C20orf116 excretion was detectable more than 24 hours before sCr rise could be measured; high level seemed to indicate severity of organ failure.
急性肾损伤(AKI)是一种危及生命的病症。尽管进行了重症监护治疗,但由于在肾小管上皮细胞损伤发生时几乎没有直接测量的指标,所以其发生率无法预测。因此,我们寻找在近端肾小管细胞内水平表达的新型肽类指标,以观察其在尿液样本中的出现情况。
建立一种检测尿C20orf116蛋白的方法。
制备针对C20orf116(也称为DDRGK1)的免疫试剂。在一项前瞻性研究中,这些试剂被用于测量99名重症监护病房患者在4至6个时间点、每隔8至24小时收集的尿液中该蛋白的存在情况。这些患者因严重感染接受治疗,并被分为4组。
1)根据RIFLE标准,10名接受AKI评估的患者C20orf116检测呈高阳性,分级为衰竭或丧失(3210±4268 ng/mL),所有患者均需要肾脏替代治疗(RRT),其中9人死亡。2)6名患有既往肾病的患者发生AKI并需要RRT,但C20orf116水平低得多(33±19),其中2人死亡。3)相比之下,在11名AKI分级为风险或损伤的患者中,4人C20orf116检测呈阳性,但程度低得多(66±43),这些患者完全康复。4)在72名患者中,25人检测呈阳性(18±12 ng/mL),不符合AKI标准,但血清肌酐(sCr)升高1.2至1.4(n = 52)。健康供体(n = 48)在任何时间点均未检测到可检测到的C20orf116。
在可测量到sCr升高之前24小时以上就能检测到C20orf116排泄;高水平似乎表明器官衰竭的严重程度。